14.01.2025 • News • Alcami • People • Contract Development And Manufacturing Organizations (CDMO)

Alcami Announces CEO Transition

Alcami, a contract development and manufacturing organization (CDMO), recently announced the resignation of its CEO, Bill Humphries. Alcami’s Board Chair and former CEO Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations.

"On behalf of the Board, I’d like to express gratitude to Bill for his leadership over the last two years during a critical time of facilities expansion and a global supply chain realignment. He was a strong advocate for our clients and the organization benefited from his leadership. I am personally grateful for his contributions and wish him all the best in his new opportunity,” commented Patrick Walsh, Interim CEO, Alcami.

Mr. Walsh served as CEO of Alcami on two previous occasions and has served as Chairman over the last four years. In addition to his duties at Alcami, he currently serves as Chairman of ANI Pharmaceuticals, Chairman of MedPharm, and is an Operating Partner at Ampersand Capital Partners.

Patrick Walsh, Interim CEO, Alcami. © Alcami

Company

Alcami Corporation

4620 Creekstone Drive
27703 Durham
US

Company contact

I am interested in:

an offer
a callback
detailed information

Your request

salutation first name last name

country phone email

Please note our data protection information for the contact form.

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Expert Insights

Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.